Company intelligence / Profile preview
Armatus Bio
Columbus, Ohio, United Statesarmatusbio.com ↗
- Ownership
- Private
- Employees
- ~8
- Development stage
- Preclinical
01
Overview
Lead candidate for CMT1A has received Orphan Drug Designation and Rare Pediatric Drug Designation, advancing toward IND-enabling studies as of Q2 2024. Also developing a preclinical vectorized RNAi asset for FSHD.[6]
- Therapeutic areas
- Neurology
- Modalities
- Vectorized RNAiAAV-based gene therapy
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Armatus Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Armatus Bio.